High-throughput screening to discover small-molecule modulators of enzymes typically relies on highly tailored substrate assays, which are not available for poorly characterized enzymes. Here we report a general, substrate-free method for identifying inhibitors of uncharacterized enzymes. The assay measures changes in the kinetics of covalent active-site labeling with broad-spectrum, fluorescent probes in the presence of inhibitors by monitoring the fluorescence polarization signal. We show that this technology is applicable to enzymes from at least two mechanistic classes, regardless of their degree of functional annotation, and can be coupled with secondary proteomic assays that use competitive activity-based profiling to rapidly determine the specificity of screening hits. Using this method, we identify the bioactive alkaloid emetine as a selective inhibitor of the uncharacterized cancer-associated hydrolase RBBP9. Furthermore, we show that the detoxification enzyme GSTO1, also implicated in cancer, is inhibited by several electrophilic compounds found in public libraries, some of which display high selectivity for this protein.
RESULTS

Fluopol-ABPP assay development for RBBP9
Fluorescence polarization is a measure of the apparent size of a fluorophore and is widely used to study molecular interactions 22 . When excited with plane-polarized light, a fluorophore emits light parallel to the plane of excitation unless it rotates in the excited state. The speed of molecular rotation and resulting extent of depolarization are inversely proportional to molecular volume. Typically, small fluorophores (o10 kDa) rotate quickly and emit depolarized light (low fluorescence polarization signal) when free in solution, but rotate more slowly and emit highly polarized light (high fluorescence polarization signal) when bound to a large molecule (e.g., a protein) 22 . We predicted that the reaction between a small-molecule activitybased probe and an enzyme would result in a time-dependent increase in fluorescence polarization signal, enabling the real-time monitoring of enzymatic activity in a homogeneous assay format ( Fig. 1) .
We selected the putative hydrolytic enzyme RBBP9 as an initial target for screening by fluopol-ABPP. RBBP9 was originally identified in a screen for gene products that confer resistance to the growthinhibitory effects of transforming growth factor (TGF)-b1 (ref. 7) . RBBP9 has also been reported to bind the retinoblastoma (RB) protein, transform rat liver epithelial cell lines and show elevated expression in primary human liver tumors 7 . Although these data suggest that RBBP9 could play an important role in cancer, to date, the biochemical functions of this enzyme have remained enigmatic. Structural genomics 23 and functional proteomic 17 studies indicated that RBBP9 is a member of the serine hydrolase superfamily, but neither substrates nor selective inhibitors for the enzyme have yet been identified 23 .
Our assay takes advantage of the known interaction between purified recombinant RBBP9 and the serine hydrolase-directed activity-based probe fluorophosphonate (FP)-rhodamine ( Supplementary  Fig. 1 online) 12, 24 . Titrations of RBBP9 and FP-rhodamine led to the identification of conditions (2 mM RBBP9, 75 nM FP-rhodamine) in which enzyme labeling generated a strong, time-dependent increase in the fluorescence polarization signal ( Fig. 2a) . No labeling was observed with a mutant RBBP9 enzyme in which the serine nucleophile is replaced by alanine (S75A) ( Fig. 2a) .
We reasoned that an RBBP9 inhibitor would slow the rate of enzyme labeling, which would in turn reduce the fluorescence polarization signal (Fig. 1a) . However, because reversible inhibitors should reduce the extent of enzyme labeling only for a limited period of time, it was essential to perform the inhibition assay under kinetically controlled conditions (that is, before the enzyme labeling reaction had reached completion 19 ). By following the time course of the FP-rhodamine-RBBP9 reaction, we identified a time point (45 min) at which partial enzyme labeling yielded a strong fluorescence polarization signal with a robust Z¢ factor of 0.71 ( Fig. 2a ). Kinetic analysis by gel-based ABPP, in which probeenzyme reactions are quenched at various time points, separated by SDS-PAGE and quantified by in-gel fluorescence scanning, confirmed partial (B60% of maximal) labeling of RBBP9 at the 45-min time point ( Supplementary Fig. 2 online). At this kinetically tractable time point, either reversible or irreversible inhibition of RBBP9 labeling should be detectable by a significant reduction of the fluorescence polarization signal. To further substantiate this premise, we performed fluorescence polarization assays in the presence of a nonfluorescent, biotinylated FP probe (FP-biotin 25 ) at a concentration matching its half-maximal inhibitory concentration (IC 50 ) value for RBBP9 inhibition as predicted from gel-based competitive ABPP assays ( Fig. 2b) . A reduction in fluorescence polarization signal strength of B50% was observed for RBBP9 in the presence of FP-biotin ( Fig. 2c) , indicating that the fluopol-ABPP assay can detect partially inhibited RBBP9.
HTS for RBBP9 inhibitors by fluopol-ABPP
We next performed a fluopol-ABPP screen for RBBP9 inhibitors in a 384-well plate format using a library of 18,974 small molecules. On each plate, we included negative-control reactions without added compounds and positive-control reactions without RBBP9 to set high and low boundaries for fluorescence polarization signals, respectively. The assay performance was consistent across plates, with robust © 2009 Nature America, Inc. All rights reserved. 
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Enzyme-bound probe Figure 1 Schematic representation of the fluopol-ABPP assay. (a,b) An enzyme is dispensed into a 384-well plate, and a different test compound is added to each well. Shown are representative wells where the test compound is an inhibitor of the enzyme (a) or is inactive (b). A fluorescent ABPP probe is then dispensed to all wells, and the plate incubated for a fixed time interval. The reaction of the probe with uninhibited enzyme (b), but not inhibited enzyme (a), will greatly increase the apparent mass of the probe, resulting in the maintenance of a strong fluorescence polarization signal. Z¢ factors and signal-to-noise ratios suitable for HTS ( Supplementary  Fig. 3 online). From this screen, we identified 35 primary hits, defined as compounds that reduced the fluorescent polarization signal for FPrhodamine labeling of RBBP9 by 450% relative to control reactions ( Fig. 3a and Supplementary Table 1 online). These hits included several quinones (e.g., 2), a,b-unsaturated ketones (e.g., 3), a bisthiocarbonate (4) and the bioactive natural product emetine (1) ( Fig. 3b ).
Secondary proteomic competitive ABPP assays
The activity-based probe used for HTS with fluopol-ABPP can also be incorporated into secondary gel-based screens to rapidly rule out false-positive and nonselective primary hits. We first evaluated 31 of the hit compounds (20 mM) against purified RBBP9 by gel-based ABPP ( Fig. 3c , upper panel). Methoxy arachidonyl fluorophosphonate (MAFP) is an irreversible inhibitor of several serine lipases 26 but does not block FP-rhodamine labeling of RBBP9 ( Fig. 3c) and was therefore included as a negative control. This assay revealed that 20 of the 31 hits blocked FP-rhodamine labeling of RBBP9 by 450%. The remaining false-positive hits likely derive from common HTS artifacts such as fluorescent compound interference or instrumentation error.
To assess their specificity, we evaluated these 20 active compounds (20 mM) by competitive ABPP in two complex proteomes-the membrane fraction of mouse brain doped with exogenous human RBBP9 ( Fig. 4a ) and the soluble fraction of RBBP9-transfected COS-7 cells (Fig. 4b) , which showed robust expression of RBBP9 (Supplementary Fig. 4 online) . Briefly, to perform this assay we added each compound to the proteome, labeled the mixture with the FPrhodamine probe, and quenched and analyzed the reaction by SDS-PAGE, as described above. Here we selected competitive ABPP assay conditions under which the majority of the serine hydrolases were not yet completely labeled by the FP-rhodamine probe so that either reversible or irreversible inhibition of most enzymes could be monitored collectively at a single time point ( Supplementary Fig. 5 online). These convenient screens identified emetine (1) as a highly selective inhibitor of RBBP9. Emetine inhibited FP-rhodamine labeling of RBBP9 with an IC 50 of 7.8 mM, but did not block the labeling of any other hydrolase at concentrations up to 1 mM (Fig. 4c) .
The proteomic ABPP assays also permitted categorization of the other 19 active compounds into two groups ( Fig. 4c ). First, thirteen compounds, including 2-4, were nonselective, inhibiting multiple hydrolases ( Fig. 4a,b ). These compounds possess potentially thiolreactive chemotypes (such as quinones and unsaturated ketones) and inhibited similar 'off-target' hydrolases, including the maleimidesensitive enzyme monoacylglycerol lipase 27 (Fig. 4a,b ). This finding suggests that these compounds may inhibit RBBP9 by alkylation of an active site cysteine residue (see below). Second, six compounds exhibited membrane-sensitive activity. For example, compound 5 blocked labeling of nearly all hydrolases in the soluble COS-7 proteome ( Fig. 4b) , but had little detectable activity against membrane-associated hydrolases (Fig. 4a) . Thus, these six compounds may be aggregation-based inhibitors, which are common falsepositives in HTS screens 28, 29 . The resistance of membrane, but not soluble, enzymes to this class of inhibitors could reflect an attenuation of their aggregation properties due to interactions with endogenous lipid bilayers, as detergents are also known to quench compound aggregation 29, 30 . Consistent with this premise, we found that increasing concentrations of the surfactant Pluronic F-127 greatly impaired the inhibitory activity of compound 5, but did not diminish the inhibitory activity of emetine ( Supplementary Fig. 6 online). 
Structure-activity relationships of emetine and RBBP9 inhibition
Emetine induces a broad range of cellular effects, including an increase in alternative splicing of the Bcl-x 31 gene, antagonism of a2-adrenergic receptors 32 , inhibition of protein synthesis and cell death. However, few protein targets of emetine have been discovered. Emetine's cytotoxic activity has historically been linked to blockade of protein translation 33 , presumably through direct interactions with the ribosome 34 ; however, less toxic structural analogs of emetine, such as the anti-amebiasis drug dehydroemetine, maintain equivalent inhibitory activity on protein translation 33 . These findings suggest the existence of still unidentified protein targets that are specifically inhibited by emetine. To explore the structure-activity relationship for inhibition of RBBP9 by emetine, we screened B75 commercially available compounds possessing structural features similar to emetine by competitive ABPP (Fig. 3d , Supplementary Figs. 7 and 8 online, and Supplementary Table 2 online). Only two additional compounds, the natural product alkaloids cephaeline (1a, Fig. 3d ) and tubusoline (1c, Fig. 3d ), inhibited RBBP9, albeit with reduced potency relative to emetine ( Fig. 3e and Supplementary Fig. 7 ). Notably, dehydroemetine (1b), which only differs from emetine by the presence of one double bond, failed to inhibit RBBP9 at concentrations up to 200 mM ( Fig. 3e and Supplementary Fig. 7 ). These data thus designate RBBP9 as the first protein target, to our knowledge, that is selectively inhibited by emetine, but not dehydroemetine.
Mechanistic characterization of RBBP9 inhibitors
From our secondary proteomic ABPP assays, we suspected that several screening hits, such as the electrophilic quinone 2, might irreversibly inhibit RBBP9. As further evidence of covalent inhibition, we noticed that compounds possessing two electrophilic moieties, such as compound 4, dimerized recombinant RBBP9 as judged by the detection of a higher migrating species by SDS-PAGE ( Fig. 3c, lower panel) . Consistent with a covalent mode of inhibition, blockade of FP-rhodamine labeling of RBPP9 by 2 was not reversed by gel filtration of the 2-RBPP9 reaction (Fig. 5a) . In contrast, gel filtration of an emetine-RBBP9 reaction completely restored the FP-rhodamine labeling of RBBP9 ( Fig. 5a) . These data indicate that emetine is a reversible RBBP9 inhibitor. Quinones are well-known alkylating agents 35 , and we reasoned that Cys163, which is two residues away from the catalytic His165 in the human RBBP9 (hRBBP9) active site 23 , might be a site of irreversible alkylation. Notably, this residue is an arginine in other RBBP9 orthologs, including those from horse, rat and mouse. This predicts that other RBBP9 orthologs should be resistant to inhibition by 2. Indeed, we found that mouse RBBP9 (mRBBP9) displays an B50-fold reduced sensitivity to 2 (Fig. 5b) , being inhibited only at concentrations where 2 indiscriminately blocks FP-rhodamine labeling of most serine hydrolases in proteomes ( Supplementary Fig. 9 online) . Selective (1) Inactive (11) Candidate aggregators (6) Thiol-reactive Supplementary Fig. 3 ). (c) Concentration-dependent effects of emetine (1) on FP-rhodamine labeling of mouse brain serine hydrolases. Note that emetine selectively inhibits RBBP9 labeling at concentrations up to 1 mM. (d) Primary hits can be segregated into four general categories based on performance in competitive proteomic ABPP assays.
hRBBP9, a Cys163Arg (C163R) mutation rendered this enzyme insensitive to 2 (Fig. 5b) . Emetine, however, exhibited similar activity against hRBBP9 (wild type), hRBBP9 (C163R) and mRBBP9 (Fig. 5c) .
These results thus provide mechanistic insights to explain how alkylating agents inhibit hRBPP9 and suggest further that emetine likely serves as a general inhibitor of mammalian RBBP9 orthologs.
GSTO1 inhibitor discovery by fluopol-ABPP
To test whether fluopol-ABPP could be applied to a second, mechanistically distinct enzyme class that reacts with a different activity-based probe, we assayed the oxidoreductase GSTO1. GSTs are cellular detoxifying enzymes that metabolize endogenous compounds, chemotherapeutic agents and by-products of oxidative stress, and have recently gained attention as potential anticancer drug targets 36 . GSTO1, in particular, is overexpressed in human cancer cell lines that show enhanced aggressiveness 15 and chemotherapeutic resistance 37 . GSTO1 is an atypical GST that utilizes a catalytic cysteine nucleophile 38 , which renders it sensitive to generic thiol-alkylating agents, such as N-ethylmaleimide 39 . However, selective GSTO1 inhibitors have not yet been identified. We previously discovered that GSTO1 reacts strongly with sulfonate ester (SE) activitybased probes 15 , which target a broad swath of metabolic enzymes in proteomes. Under conditions similar to those of the RBBP9 assay, the reaction of GSTO1 (1 mM) and an SE-rhodamine probe (75 nM) (Supplementary Fig. 1 ) generated a robust, time-dependent increase in the fluorescence polarization signal (Fig. 6a) . No labeling was seen with a mutant GSTO1 enzyme in which the catalytic cysteine was converted to alanine (C32A), or in the presence of 1 mM glutathione, a known inhibitor of probe labeling 15 (Fig. 6a) . A time course of the SErhodamine-GSTO1 reaction identified a time point (90 min) at which partial GSTO1 labeling yielded a strong increase in fluorescence polarization signal with a robust Z¢ factor of 0.67. Under these conditions, we screened 2,000 compounds (5 mM) in a 384-well plate format and identified 38 primary hits that reduced the fluorescence polarization signal by 450% (Supplementary Table 3 online). This 2,000-compound library also contained six primary hits from the RBBP9 screen. Notably, five of these six compounds also registered as hits for GSTO1, with the only exception being emetine (1), which did not block probe labeling of GSTO1.
Among the GSTO1 primary hits were, not surprisingly, 20 potentially thiol-reactive compounds, including the thiol-reactive RBBP9 inhibitor 3, the proton pump inhibitor omeprazole (6), the disulfide 7 and the a-chloroacetamide 8 (Fig. 6b) . In addition, we identified 11 phenols, a chemotype known to inhibit GSTs 40 , including the antibiotic rifampicin (9) (Fig. 6b) . Gel-based ABPP with recombinant GSTO1 confirmed the inhibitory activity for a representative subset of compounds. Compounds 7 and 8 potently inhibited GSTO1, each with IC 50 o 0.4 mM (Fig. 6b) . Gel filtration studies indicated that these inhibitors act by an irreversible mechanism, in contrast to 6 and 9, which behaved as lower potency, reversible inhibitors of GSTO1 ( Fig. 6c) .
To assess the selectivity of compounds 6-9, we evaluated them by competitive ABPP using the soluble proteome of a human breast cancer cell line (MDA-MB-231) that expresses high endogenous levels of GSTO1. (Fig. 6d,e ). Here, we again selected assay conditions where the majority of the probe targets were not yet completely labeled ( Supplementary Fig. 5 ). We also included the previously identified RBBP9 inhibitors emetine (1), quinone 2 and unsaturated ketone 3 in this analysis. Each of the hit compounds inhibited GSTO1 at 20 mM, although 6 and 9 were considerably less potent than 2, 3, 7 and 8 (Fig. 6d) . At this concentration, however, 2, 7 and 8 also inhibited the SE-rhodamine labeling of several other proteins in the MDA-MB-231 proteome, whereas compound 3 appeared to activate labeling of an 80-kDa band. We have previously identified this protein as type 2 tissue transglutaminase 41 , a protein that is activated by several cofactors (GTP, calcium) 42 . In contrast, emetine (1) did not inhibit the labeling of GSTO1 or any of the other SE-rhodamine targets. Interestingly, when we lowered the concentration of inhibitors to 1 mM, compound 8 maintained strong inhibition of GSTO1, whereas the activities of compounds 2, 3, 6, 7 and 9 were lost (Fig. 6e) . Moreover, at this concentration, 8 showed good selectivity for GSTO1 in the MDA-MB-231 proteome (Fig. 6e) . We finally confirmed that 8 was a potent inhibitor of GSTO1 (IC 50 ¼ 120 nM) using an S-4-(nitrophenacyl)glutathione substrate assay 43 (Supplementary Fig. 10  online) . These data indicate that the tempered a-chloroacetamide © 2009 Nature America, Inc. All rights reserved. electrophile of 8 offers a window for potent and selective inhibition of GSTO1. The other GSTO1 hits that showed potent inhibition of purified enzyme, but greatly reduced activity in proteomes (compound 7), are likely reactive with many proteins and metabolites in the cellular environment, thereby reducing potency for GSTO1 and ablating any selectivity window for GSTO1.
DISCUSSION
Complete genome sequences have revealed that eukaryotic and prokaryotic organisms possess a huge number of uncharacterized proteins 6 . Even for proteins that may be considered 'annotated' , we have yet, in most instances, to achieve a complete understanding of their biochemical, cellular and physiological functions. A central component of efforts to annotate the proteome is the development of selective pharmacological probes to perturb the function of individual proteins in native biological settings. The success of HTS to uncover such probes, as exemplified by the National Institutes of Health Molecular Libraries Screening initiative (http://nihroadmap.nih.gov/molecularlibraries/), hinges on the advancement of high-quality screens, which is particularly challenging for proteins whose biochemical function is poorly characterized. Fluopol-ABPP addresses this problem by enabling HTS for potentially hundreds of such enzymes that lack traditional substrate assays, but react with activity-based probes.
We used fluopol-ABPP to analyze the cancer-associated hydrolase RBBP9 and discovered that this protein is inhibited by the natural product emetine. Notably, emetine did not inhibit any of the other serine hydrolases detected in our proteomic ABPP studies. The RBBP9-emetine interaction displayed a tight structure-activity relationship, with chemical analogs, such as dehydroemetine, lacking activity. These data suggest that RBBP9 could be a relevant target to explain the molecular mechanisms underlying the bioactivity of emetine and related ipecac alkaloids, and, conversely, that these natural products may offer useful probes for exploring the enzymatic functions of RBBP9 in biological systems. Our finding that RBBP9, as well as several other serine hydrolases, were susceptible to inactivation by thiol-reactive electrophilic compounds (quinones, disulfides) suggests that this class of enzymes might be regulated by endogenous pathways for posttranslational modification of cysteines (e.g., nitroyslation 44 , oxidation 45 and electrophilic modification 46 ).
We also applied fluopol-ABPP to discover the a-chloracetamide 8 as a selective, covalent inhibitor for a second cancer-associated enzyme, GSTO1. Notably, RBBP9 and GSTO1 are mechanistically distinct enzymes (serine hydrolase and reductase/thioltransferase, respectively) targeted by different classes of ABPP probes (FP and SE, respectively). The application of fluopol-ABPP to discover both reversible and irreversible inhibitors for each of these proteins underscores the versatility of this method. Indeed, for RBBP9, it is difficult to conceive of another HTS-compatible biochemical assay, because, despite much effort 23 , substrates have not yet been identified for this enzyme. In the case of GSTO1, a limited number of substrate assays have been developed, but these are not well-suited for HTS (e.g., UV absorbance assays at short wavelengths (305 nm) where many smallmolecules exhibit intrinsic absorbance 43 ). Thus, fluopol-ABPP should prove valuable not only for uncharacterized enzymes but also for enzymes with substrate assays that are not readily adaptable to an HTS format.
The range of proteins amenable to HTS has been expanded by a handful of complementary assays, such as fluorescence polarization technologies that use aptamers 47 or reversibly binding small molecules 48 as probes. Although aptamers are applicable to proteins of poorly characterized function, individual aptamers must be developed for each target (or set of structurally related targets). In contrast, each ABPP probe can target 4100 enzymes that are structurally quite divergent 13, 17, 49 , making this approach amenable to screening a large fraction of the proteome. ABPP also offers straightforward secondary assays to rapidly assess compound activity and selectivity in complex biological samples, such that nonspecific compounds (e.g., compounds 2 and 7; see Figs. 4 and 6, Supplementary Fig. 11 online) and compounds showing odd behavior (e.g., compound 5) can be discarded in favor of inhibitors that selectively block their intended target in proteomes (e.g., emetine for RBBP9 and compound 8 for GSTO1). These secondary proteomic selectivity assays are more difficult to perform with reversibly binding small-molecule probes.
Fluopol-ABPP is limited to enzymes for which cognate activitybased probes have been developed. Although this includes many important enzyme classes (hydrolases, proteases, kinases and oxidoreductases) 10, 11 , several others remain outside the current scope of ABPP. It is also important to recognize that blockade of probe labeling may not equate in all cases with inhibition of an enzyme's catalytic activity. Secondary substrate assays can readily address this concern for some enzymes (as we showed for GSTO1) but may not be available for poorly characterized enzymes (such as RBBP9). Nonetheless, competitive ABPP has identified potent and selective inhibitors for many enzymes 10, 11 , and we expect that probe labeling will usually be a valid surrogate for the catalytic activity of enzymes. Finally, fluopol-ABPP requires a substantial amount of purified protein (B4 nmol/384-well plate), which may prove challenging for certain enzymes (e.g., transmembrane enzymes). The quantity of enzyme could be substantially reduced by performing the assay in 1,536-well plate format or by conducting labeling reactions for a longer period of time. Regardless, in cases where protein quantity is not limiting, fluopol-ABPP is quite inexpensive, as the quantity of probe used per assay is negligible (0.3 nmol/384-well plate). We thus anticipate that efforts to advance the large-scale production of proteins, such as those of structural genomics initiatives 50 , should dovetail nicely with chemical proteomic studies that provide target proteins and probes for the construction of fluopol-ABPP HTS assays. The pharmacological tools that emerge from these screens should propel future investigations that aim to functionally annotate the proteome. 24 , FP-rhodamine 23 , SE-rhodamine 40 , and S-4-(nitrophenacyl)glutathione 42 were synthesized following previously described protocols. Emetine, glutathione, methyl arachidonoyl fluorophosphonate (MAFP), omeprazole and rifampicin were purchased from Sigma. Compounds 2, 4 and 5 were purchased from Ryan Scientific, and compounds 3, 7, 8 and 69-138 were purchased from BioFocus DPI. Emetine analogs 1a-g were obtained from the National Cancer Institute. Screening compound libraries are described in the Supplementary Methods online.
METHODS
Materials. FP-biotin
Recombinant protein expression and purification. Full-length cDNA encoding human RBBP9 in pcDNA3 (Invitrogen) was a gift of the Cheresh laboratory, and full-length cDNA encoding mouse RBBP9 was purchased from Open BioSystems. GSTO1 was obtained as an expressed sequence tag from Invitrogen. These genes were subcloned into pTrcHisB (Invitrogen). Point mutants were generated using the Quikchange Site-Directed Mutagenesis Kit (Stratagene). The constructs were expressed in BL21(DE3) Escherichia coli and purified as described in the Supplementary Methods.
Fluopol-ABPP Assays. The RBBP9 fluopol-ABPP assay was performed in a 384-well format. Briefly, 10 ml of recombinant RBBP9 (2.2 mM) in assay buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.01% Pluronic F-127 (Invitrogen)) was added to test compound and negative control wells, and 10 ml assay buffer alone was added to positive control wells. Compounds were then added to test compound wells and DMSO to control wells, and plates were then incubated at 25 1C for 30 min. FP-rhodamine (1.1 ml; 750 nM in assay buffer; 75 nM final concentration in fluorescence polarization assay) was added to all wells. The plates were incubated for an additional 45 min at 25 1C and then read on an Envision plate reader (Perkin Elmer).
The GSTO1 fluopol-ABPP assay was similarly performed in a 384-well format. Briefly, 10 ml of GSTO1 (1.1 mM) in assay buffer was added to test compound and negative-control wells, and 10 ml of assay buffer alone to positive-control wells. Compounds were added to test compound wells and DMSO to control wells. Plates were then incubated at 25 1C for 30 min. SE-rhodamine (1.1 ml; 750 nM in assay buffer) was added to all wells. The plates were incubated for 90 min at 25 1C and then read.
Gel-based ABPP experiments with recombinant enzyme. Initial secondary gel-based ABPP analysis of primary hits was performed under the same conditions as the corresponding fluopol-ABPP assay. Briefly, recombinant RBBP9 (2 mM) in assay buffer was incubated with DMSO or indicated compound (20 mM) for 30 min at 25 1C before the addition of FP-rhodamine at a final concentration of 75 nM in 50 ml total reaction volume. The reaction was incubated for 45 min at 25 1C, quenched with 2Â SDS-PAGE loading buffer, boiled for 5 min at 90 1C, separated by SDS-PAGE and visualized in-gel using a flatbed fluorescence scanner (Hitachi). The percentage activity remaining was determined by measuring the integrated optical density of the bands. Similarly, recombinant GSTO1 (1 mM) in assay buffer was incubated with DMSO or indicated compound (20 mM) for 30 min at 25 1C in a 50 ml total reaction volume. SE-rhodamine (75 nM final concentration) was then added, and the reaction was incubated at 25 1C for 90 min before it was similarly quenched and analyzed. For the determination of compound IC 50 values using ABPP, the overall procedure remained the same but with conditions that enabled the use of less enzyme (400 nM RBBP9, 1 mM FP-rhodamine, 10 min; 400 nM GSTO1, 1 mM SE-rhodamine, 20 min). IC 50 values were determined from dose-response curves from three trials at each inhibitor concentration (0.1-100 mM) using Prism software (GraphPad). For experiments involving gel-filtration of recombinant enzyme to test compound reversibility, discussed in detail in the Supplementary Methods, the reactions were set up similarly with the exception that a fraction of the enzyme-inhibitor mixture was passaged over a Sephadex G-25M column (GE Healthcare) before the reaction with the ABPP probe.
Competitive ABPP assays in proteomes. The mouse brain membrane proteome, prepared as described in Supplementary Methods, was diluted to 1 mg/ml in PBS. Recombinant RBBP9 (400 nM) was added for comparison where indicated. Similarly, the soluble proteome of transfected COS-7 cells, prepared as described in Supplementary Methods, was diluted to 1 mg/ml in PBS. These proteomes were preincubated with either DMSO or candidate inhibitor at the indicated concentration in a 50 ml reaction volume for 30 min at 25 1C. FP-rhodamine was then added at a final concentration of 1 mM. After 10 min, the reactions were quenched and analyzed as described above. The soluble fraction of the human breast cancer cell line MDA-MB-231, prepared as described in Supplementary Methods, was diluted to 2 mg/ml in PBS. The proteome was preincubated with either DMSO or candidate inhibitor at the indicated concentration in a 50 ml reaction volume for 30 min at 25 1C, and SE-rhodamine was added at a final concentration of 5 mM. After 1 h, the reactions were quenched and analyzed as described above.
GSTO1 substrate assay. This assay was performed as previously described 42 and is detailed in the Supplementary Methods.
Note: Supplementary information is available on the Nature Biotechnology website.
